Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Esophageal Cancer, Neoadjuvant Therapy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this clinical study is to conduct a multi-center, big data study to create a neural network decision model for predicting treatment efficacy and prognosis based on multi-modal, multi-temporal imaging features combined with tumor microenvironment scores. It will also use various model interpretation techniques to clarify the role and mechanism of key biomarkers or strongly associated biomarker groups in treatment efficacy and prognosis. Ultimately, it aims to achieve the research and application of AI treatment strategies combining multi-modal imaging and digital pathology to guide clinicians in the personalized treatment strategies for patients with esophageal squamous cell carcinoma.
Primary outcome measures
- Pathological Complete Response (pCR) Rate [Time frame: January 2025 - December 2027]
- Overall Survival (OS) [Time frame: January 2025 - December 2027]
- Event-Free Survival (EFS) [Time frame: January 2025 - December 2027]
- Disease-Free Survival (DFS) [Time frame: January 2025 - December 2027]
Eligibility criteria
Inclusion criteria
- Aged 18-70 years;
- Histologically confirmed esophageal carcinoma by biopsy;
- No prior antitumor therapy received.
Exclusion criteria
- Contraindications to MRI examination;
- Poor compliance with antitumor therapy;
- Unwillingness to participate in the study;
- Image quality inadequate for diagnostic requirements.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07203690 · 2025-066